Pay-for-delay patent settlements on the rise, prompting fierce debate
Patent dispute settlements between brand-name and generic drug manufacturers that delay the time lower-cost medications reach the market are sharply rising, according to a recent Federal Trade Commission staff report. FTC...
Subscription required to view this article.This content can only be accessed by FTCWatch subscribers. If you are an FTCWatch subscriber, please login to access this content
If you do not currently subscribe to FTCWatch please contact us for subscription information: